

# People

## Jerry Lanchbury joins Myriad Genetics

Myriad Genetics (<http://www.myriad.com>) has announced the appointment of Jerry Lanchbury as Senior Vice President of Research and Development. Lanchbury joined Myriad from Kings College London, UK, where he was Head of the Molecular Immunogenetics Unit at the GKT School of Medicine. Lanchbury also founded Immune Regulation, a privately held biotherapeutics company in the UK. Peter Meldrum, President and CEO of Myriad said: 'I am pleased to extend a warm welcome to Dr Lanchbury. His experience in running a large research organization and ability to motivate his team to drive the success of the company will serve him and Myriad Genetics well.'

## New Director at Astex

Astex Technology (<http://www.astex-technology.com>) has appointed David Rees as Director of Medicinal Chemistry. Rees joins Astex with more than 19 years of experience as a medicinal chemist in the pharmaceutical industry. He has held positions at Parke-Davis, Organon, and arrives at Astex from AstraZeneca, where he was Director and head of the Medicinal Chemistry Department at the company's R&D headquarters in Mölndal, Sweden. Rees began his career at Cambridge University, UK, as an organic chemist before moving to Harvard University. He has over 60 publications and patents in the applications of peptidomimetic chemistry, combinatorial chemistry and supramolecular chemistry to drug discovery. Robin Carr, Vice President of Drug Discovery, said: 'We are delighted to have recruited David at this important stage in the company's development'.

## New VP Drug Discovery at Achillion Pharmaceuticals

Milind Deshpande has been promoted to Vice President, Drug Discovery at Achillion Pharmaceuticals (<http://www.achillion.com>), a privately held pharmaceutical company focused on the discovery and development of small-molecule drugs that combat drug resistance in infectious diseases. Deshpande's new role expands on his previous position as Vice President, Chemistry.

'Since joining Achillion in 2001, Milind has led the expansion of the company's

chemical synthesis capabilities, dramatically increased our compound library and established important new drug discovery programs to address key unmet medical needs in infectious diseases,' said William G. Rice, CEO of Achillion. 'In this newly created position, Dr Deshpande will contribute to the strategic vision for Achillion's drug discovery efforts, as well as direct the exploration of new infectious disease targets and the identification of important new drug candidates to add to Achillion's clinical development pipeline.'

Deshpande has more than 15 years experience of working in the infectious diseases field. Before joining Achillion, Deshpande was Associate Director of Lead Discovery and Early Discovery Chemistry at Bristol Myers Squibb Pharmaceutical Research Institute where he played a role in establishing the high-throughput synthesis infrastructure. Before this, Deshpande held a faculty position at Boston University Medical School.

## New CSO at Accelrys

Scott Kahn has been recently appointed as Chief Science Officer, Worldwide Operations, at Accelrys (a wholly owned subsidiary of Pharmacia; <http://www.accelrys.com>). Kahn will manage Accelrys' global research and development organization, which focuses on the design and production of software and IT solutions for the pharmaceutical industry. Kahn was previously General Manager and Senior Vice President of Accelrys' life sciences division. Following a PhD in theoretical chemistry at the University of California, Irvine, Kahn did postdoctoral work at Cambridge University, UK, and was an Assistant Professor of Chemistry at the University of Illinois, Urbana-Champaign.

Mark Emkjer, President of Accelrys, said: 'For the past 12 years, Scott has worked tirelessly with leading scientists to evangelize computational chemistry and informatics as an essential part of the R&D process. I believe that his knowledge and insight has contributed significantly to Accelrys' scientific innovation and market leadership.'

## Targesome appoints new President and CEO

George Dunbar has been appointed as President and Chief Executive Officer of

Targesome (<http://www.targesome.com>), a privately held biopharmaceutical company that focuses on nanoparticle technology for targeted drug delivery. Dunbar was most recently CEO of Epic Therapeutics, a drug delivery company that completed a successful merger with Baxter Healthcare Corp. in 2002. He was also a founding member of iCEO, a service provider of executive talent to early stage companies. Before joining Epic, Dunbar was Acting President and CEO of CytoTherapeutics and StemCells. He was also the first President and CEO of Metra Biosystems, and, earlier, held senior management positions with the Ares-Serono group, Amersham and Motorola.

On his appointment, Dunbar commented: 'I am excited by the opportunity to help Targesome commercialize its technology. Using the advantages of our proprietary nanoparticle platform, I believe we can provide a significant therapeutic advantage in oncology and other disease areas.'

## Mary Callan joins Morphotek

Morphotek (<http://www.morphotek.com>), a biotechnology company that focuses on generating proprietary organisms for drug development, has appointed Mary Callan as Vice President, Business Development. Before joining Morphotek, Callan was Director of Business Development at Exelixis, and previously Head of Business Development at Large Scale Biology Corp., where she had a key role in the team responsible for the company's successful initial public offering. Callan has experience of business development across a wide variety of corporate sectors, including pharmaceuticals, genomics, proteomics and biomanufacturing. She began her career in research at BASF Corp. in the USA, before being promoted to their business development division at the company headquarters in Germany. Nicholas C. Nicolaides, President and CEO of Morphotek, commented: 'I am delighted to have a person with Mary's experience in out-licensing and corporate development leading these business development efforts.'

People was written by  
*Joanna Owens*